1.05 USD
▲0.00+0.96%
盘后 1.04 -0.48%
2026-08-03
市值
$65.02M
市盈率
—
EPS
-1.84
股息率
—
52 周区间
1.03 – 1.95
成交量
259.71K
Beta
1.22
目标价
2.50
52W 低 1.0352W 高 1.95
价格走势
公司简介
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company’s lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of αvß8 and αvß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based target-mediated drug delivery. Pliant Therapeutics,...